Adverse effects (any adverse effect) · sickle cell disease
It is very uncertain whether omega‐3 changes adverse effects (any adverse effect) compared with placebo (very low certainty).
1 finding from 1 review
Frequency of hospitalization · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of sickle cell‐related complications · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Haemoglobin status · sickle cell disease
It is very uncertain whether omega‐3 changes haemoglobin status compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Frequency of hospitalization · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute chest syndrome ( · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes frequency of sickle cell‐related complications: acute chest syndrome compared with placebo (very low certainty).
1 finding from 1 review
Haemoglobin status · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
1 finding from 1 review
Frequency of crisis · people with sickle cell disease
Zinc showed no clear difference in frequency of crisis compared with placebo (low certainty).
1 finding from 1 review
Severity of pain · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR), All bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis may leads to higher proportion with zero bleeds compared with on‐demand therapy (low certainty).
1 finding from 1 review